EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer

Tongchen He, Caleb Cheng iD, Yuanyuan Qiao iD, Hanbyul Cho, Eleanor Young, Rahul Mannan iD, Somnath Mahapatra, Stephanie J Miner iD, Yang Zheng, NamHoon Kim, Victoria Z Zeng, Jasmine P Wisniewski und 17 weitere

Proceedings of the National Academy of Sciences · 09.04.2024 · 121 (15)

DOI: 10.1073/pnas.2322563121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024-04. Verfasst von Tongchen He und 28 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109. Hauptthemen laut MEDLINE: Adenosine Triphosphatases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, James M. Cox Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mammalian switch/sucrose nonfermentable (mSWI/SNF) ATPase degraders have been shown to be effective in enhancer-driven cancers by functioning to impede oncogenic transcription factor chromatin accessibility. Here, we developed AU-24118, an orally bioavailable proteolysis-targeting chimera (PROTAC) degrader of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1. AU-24118 demonstrated tumor regression in a model of castration-resistant prostate cancer (CRPC) which was further enhanced with combination enzalutamide treatment, a standard of care androgen receptor (AR) antagonist used in CRPC patients. Importantly, AU-24118 exhibited favorable pharmacokinetic profiles in preclinical analyses in mice and rats, and further toxicity testing in mice showed a favorable safety profile. As acquired resistance is common with targeted cancer therapeutics, experiments were designed to explore potential mechanisms of resistance that may arise with long-term mSWI/SNF ATPase PROTAC treatment. Prostate cancer cell lines exposed to long-term treatment with high doses of a mSWI/SNF ATPase degrader developed SMARCA4 bromodomain mutations and ABCB1 (ATP binding cassette subfamily B member 1) overexpression as acquired mechanisms of resistance. Intriguingly, while SMARCA4 mutations provided specific resistance to mSWI/SNF degraders, ABCB1 overexpression provided broader resistance to other potent PROTAC degraders targeting bromodomain-containing protein 4 and AR. The ABCB1 inhibitor, zosuquidar, reversed resistance to all three PROTAC degraders tested. Combined, these findings position mSWI/SNF degraders for clinical translation for patients with enhancer-driven cancers and define strategies to overcome resistance mechanisms that may arise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine TriphosphatasesProstatic Neoplasms, Castration-ResistantMaleHumansRatsMiceAnimalsCell LineChromatinMammalsAndrogen Receptor AntagonistsDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

ABCB1SMARCA2SMARCA4mSWI/SNFproteolysis-targeting chimera (PROTAC)

Substanzen

Adenosine TriphosphatasesChromatinAndrogen Receptor AntagonistsSMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
  • Department of Pathology, University of Michigan, Ann Arbor, MI 48109.
  • Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • Medical Scientist Training Program, University of Michigan, Ann Arbor, MI 48109.
  • Cellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI 48109.
  • Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109.

ORCID-Profile: Caleb Cheng, Yuanyuan Qiao, Rahul Mannan, Stephanie J Miner, Rui Wang, Costas A Lyssiotis, Arul M Chinnaiyan

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS
  • James M. Cox Foundation
  • Prostate Cancer Foundation
  • HHS | NIH | National Cancer Institute
  • U.S. Department of Defense
  • HHS | National Institutes of Health

Zitieren

APA

He, T., Cheng, C., Qiao, Y., Cho, H., Young, E., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N., Zeng, V. Z., Wisniewski, J. P., Hou, S., Jackson, B., Cao, X., Su, F., Wang, R., Chang, Y., Kuila, B., …, & Chinnaiyan, A. M. (2024). Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proceedings of the National Academy of Sciences, 121(15). https://doi.org/10.1073/pnas.2322563121

Vancouver

He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, et al. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer. Proceedings of the National Academy of Sciences. 2024;121(15). doi:10.1073/pnas.2322563121

BibTeX
@article{He2024,
  author = {He, Tongchen and Cheng, Caleb and Qiao, Yuanyuan and Cho, Hanbyul and Young, Eleanor and Mannan, Rahul and Mahapatra, Somnath and Miner, Stephanie J and Zheng, Yang and Kim, NamHoon and Zeng, Victoria Z and Wisniewski, Jasmine P and Hou, Siyu and Jackson, Bailey and Cao, Xuhong and Su, Fengyun and Wang, Rui and Chang, Yu and Kuila, Bilash and Mukherjee, Subhendu and Dukare, Sandeep and Aithal, Kiran B and D S, Samiulla and Abbineni, Chandrasekhar and Vaishampayan, Ulka and Lyssiotis, Costas A and Parolia, Abhijit and Xiao, Lanbo and Chinnaiyan, Arul M},
  title = {Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {15},
  doi = {10.1073/pnas.2322563121}
}
Kostenlos starten →